Branded

Allergan adds new board director
DUBLIN — Allergan on Monday announced the addition of Adriane M. Brown to its board of directors, effective February 2017. Brown serves as president and CEO of private global invention company Intellectual Ventures.

"I am pleased to join the board of Allergan as they deliver results around the world that serve their customers and patients," said Brown. "Their commitment to innovative and meaningful work with the goal of helping people live longer and healthier is commendable."
FDA approves Gilead’s hepatitis B treatment Vemlidy
SILVER SPRINGS, Md. — The Food and Drug Administration has approved Vemlidy (tenofovir alafenamide, TAF, 25 mg), a new once-daily treatment for hepatitis B infection with compensated liver disease from Gilead Sciences. Vemlidy comes with a boxed warning about the risk of lactic acidosis/severe hepatomegaly with steatosis and post-treatment severe acute exacerbation of hepatitis B.

WSJ: Parts of Affordable Care Act appealing to Trump
HDA releases 2 pilot studies in advance of Drug Supply Chain Security Act implementation

ARLINGTON, Va. — The Healthcare Distribution Alliance on Thursday presented two viable scenarios out of its Pilot Study for Saleable Returns, a study designed to help pharmaceutical manufacturers and distributors comply with requirements set forth by the Drug Supply Chain Security Act.
Allergan launches Taytulla softgel contraceptive

DUBLIN — Allergan on Thursday announced the launch of its Taytulla norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules, 1mg/20mcg), the first softgel capsule oral contraceptive.
Rx-360 launches redesigned website

WASHINGTON — International pharmaceutical supply chain consortium Rx-360 on Thursday announced the launch of a new website at its annual Rx-360 Conference in Gaylord National Harbor in Maryland. The consortium said the redesign is part of its digital evolution to showcase its industry expertise and support its overall growth.
Report: Trump victory could boost pharmaceutical stocks
Novartis' Heart Partner app integrated into Walgreens Balance Rewards

DEERFIELD, Ill. - Walgreens on Monday announced the integration of Novartis' Heart Partner app to its Balance Rewards for Health Choices API.

"For [heart failure] patients it is sometimes difficult to keep up with a healthier lifestyle and managing their treatment," Walgreens developer evangelist Drew Schweinfurth posted in a blog. "The newly developed Heart Partner app helps coordinate care in a simple and easy way. The app allows for tracking daily activity and vitals such as blood pressure or weight [and] medication compliance."
FDA approves Propeller platform for use with GSK’s Ellipta

MADISON, Wis. — The Food and Drug Administration has cleared Propeller Health’s Propeller platform — a leading digital solution for respiratory medicine — to be used with GSK’s Ellipta, its dry powder inhaler.
Jean Coutu Group continues flu awareness campaign

Allergan adds new board director

FDA approves Gilead’s hepatitis B treatment Vemlidy

WSJ: Parts of Affordable Care Act appealing to Trump

HDA releases 2 pilot studies in advance of Drug Supply Chain Security Act implementation

Allergan launches Taytulla softgel contraceptive

Rx-360 launches redesigned website

Report: Trump victory could boost pharmaceutical stocks

Novartis' Heart Partner app integrated into Walgreens Balance Rewards

FDA approves Propeller platform for use with GSK’s Ellipta

Jean Coutu Group continues flu awareness campaign